Lipids in Coronary Heart Disease: From Epidemiology to Therapeutics

Seth S. Martin, Parag H. Joshi, Erin D. Michos

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Dyslipidemia is a major contributor to the large burden of atherosclerotic cardiovascular disease (ASCVD) in the United States and around the world. The 2013 ACC/AHA guidelines recommend statins as first line pharmacologic therapy, with the intensity of statins matched to the absolute ASCVD risk of the patient. In special circumstances, other lipid-lowering therapies may be considered for add-on therapy. However, many high-risk patients treated with statins still have a significant residual burden of atherogenic lipoprotein particles or cannot tolerate a maximal statin dose. In these cases, newer therapies stemming from rapid adoption of translational research (such as PCSK9 (. proprotein convertase subtilisin/kexin type 9) inhibitors) show potential promise, while others (such as CETP (cholesteryl ester transfer protein) inhibitors) give reason for pause. In this chapter, we will review the epidemiology of the major lipid fractions (LDL-C (low-density lipoprotein cholesterol), HDL-C (high-density lipoprotein cholesterol), and triglycerides) with ASCVD risk, discuss therapeutic interventions from lifestyle and pharmacologic therapies, and highlight promising areas of translational research as it pertains to future drug developments for the management of patients with or at high-risk for coronary artery disease.

Original languageEnglish (US)
Title of host publicationTranslational Research in Coronary Artery Disease
Subtitle of host publicationPathophysiology to Treatment
PublisherElsevier Inc.
Number of pages14
ISBN (Print)9780128023853
StatePublished - Jan 1 2016


  • High-density lipoprotein cholesterol
  • Lipid-lowering medications
  • Lipids
  • Low-density lipoprotein cholesterol
  • Statins
  • Triglycerides

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Lipids in Coronary Heart Disease: From Epidemiology to Therapeutics'. Together they form a unique fingerprint.

Cite this